Moderna, Inc. $MRNA Stake Lessened by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 29.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 314,872 shares of the company’s stock after selling 132,808 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Moderna were worth $15,995,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. MUFG Securities EMEA plc acquired a new position in Moderna during the second quarter valued at $28,000. Flagship Harbor Advisors LLC acquired a new stake in Moderna during the 4th quarter worth about $31,000. Canton Hathaway LLC acquired a new stake in Moderna during the 1st quarter worth about $31,000. Cromwell Holdings LLC boosted its position in Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after acquiring an additional 341 shares during the period. Finally, EverSource Wealth Advisors LLC grew its stake in Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $54.82 on Friday. The firm has a market cap of $21.75 billion, a P/E ratio of -6.86 and a beta of 0.94. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $85.60. The stock’s 50-day moving average is $59.37 and its two-hundred day moving average is $52.51.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the previous year, the business posted ($2.13) EPS. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. Analysts predict that Moderna, Inc. will post -6.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, May 26th. Royal Bank Of Canada boosted their price objective on shares of Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Wolfe Research reiterated an “underperform” rating and issued a $25.00 price objective on shares of Moderna in a research note on Monday, July 20th. Morgan Stanley increased their target price on shares of Moderna from $33.00 to $39.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Moderna has an average rating of “Reduce” and an average target price of $40.00.

Insider Activity at Moderna

In other news, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the transaction, the director owned 3,924 shares in the company, valued at $183,800.16. This represents a 70.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 119,406 shares of company stock valued at $5,928,762. 10.80% of the stock is currently owned by corporate insiders.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported second-quarter EPS of -$1.97, better than the roughly -$2.03 consensus and an improvement from -$2.13 a year earlier. Revenue was approximately $145 million, while management reiterated its plan for up to 10% revenue growth in 2026. Moderna Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: The company improved its 2026 operating-expense outlook by about $200 million and now expects year-end cash of $4.7 billion to $5.2 billion, supporting its effort to reduce cash burn. Moderna also faces a potentially important catalyst on August 5, when regulators are scheduled to decide on its seasonal flu vaccine candidate, mFLUSIVA. Moderna Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Trading activity showed elevated interest in Moderna call options, with 82,913 contracts acquired versus a typical daily volume of 48,590. This may indicate speculative bullish positioning, but options activity alone does not establish a sustained change in investor sentiment.
• Negative Sentiment: Moderna’s Phase 3 mRNA-1403 norovirus vaccine trial did not meet the statistical criteria for early success at its interim analysis. The company plans to add another participant cohort, extending the trial into a fourth season and delaying clarity on a potential commercial opportunity. Moderna Adds New Cohort to Phase III Vaccine Trial
• Negative Sentiment: Investors remain concerned about Moderna’s dependence on declining COVID-19 vaccine sales. Although the quarterly loss narrowed, the company still posted a GAAP net loss of about $782 million, and reports characterized revenue as weaker than Wall Street expected. The norovirus setback therefore outweighed the earnings and cost-control improvements. Moderna Misses Quarterly Revenue Estimates on COVID Vaccine Weakness

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.